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Aim To assess the effect of liver damage on methadone 
metabolism in opiate addicts undergoing methadone 
maintenance treatment (MMT).
Methods This cross-sectional study recruited 74 patients 
treated at the outpatient clinic of Public Health Institute 
of Split-Dalmatia County from 2013-2016. Concentrations 
of methadone and its main inactive metabolite were mea-
sured in participants’ biological samples on regular check-
ups. Urine samples obtained before oral methadone in-
take, and blood and urine samples obtained 90 minutes 
after methadone intake were analyzed using gas chroma-
tography/mass spectrometry. Participants were divided 
into groups according to liver damage criteria: hepatitis C 
virus status (positive, negative, or clinical remission); aspar-
tate aminotransferase to platelet ratio (APRI) index (<0.7 
and ≥0.7); and fibrosis-4 score (<1.45, 1.45-3.25, >3.25).
Results Metabolic ratio and methadone metabolite con-
centration in plasma decreased linearly with HCV infection 
status by the factor of 1.67 (P = 0.001) and 2.2 (P = 0.043), re-
spectively. Metabolic ratio in plasma decreased in patients 
with APRI index ≥0.7 by the average factor of 2.12 (P = 0.01) 
and methadone metabolite concentration in plasma de-
creased by the factor of 6.16 (P = 0.009). Metabolic ratio 
in urine decreased with the severity of fibrosis-4 score by 
the average factor of 1.63 (P = 0.008), whereas methadone 
metabolite concentration decreased by the factor of 3.53 
(P = 0.007).
Conclusion Liver damage decreases methadone metabo-
lism. Indices of liver function should be calculated regularly 
during MMT for methadone dose titration. Received: August 3, 2018
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Methadone maintenance treatment (MMT) is a common 
treatment approach for patients with opiate addiction 
(1). Physicians should individually evaluate the addiction 
phase and stage, together with psychological and social 
factors affecting the treatment course (2). Methadone 
dose enhancement is mainly based on patient’s subjective 
opinion of therapy effectiveness and clinician’s empirical 
judgement rather than on objective findings (3). Individ-
ual response to methadone varies because of genetic and 
proteomic differences as well as common psychological 
and mental comorbidities (4,5) that interfere with meth-
adone metabolism by increasing toxicity and drug side 
effects (1). The main dose-dependent adverse effects of 
chronic methadone use are cardiotoxicity (1), nephrotoxic-
ity (6), and behavioral/cognitive disorders (7,8). Therefore, 
clinicians should have these toxic effects in mind when op-
timizing MMT and determining the lowest effective dose 
for each individual. Furthermore, chronic addiction is a ma-
jor epidemiological and social problem, especially since 
frequent comorbidities make the treatment challenging. 
Promiscuity, unprotected sexual intercourses, and drug 
injectors sharing (9) in this population lead to increased 
transmission of hepatitis C virus (HCV), hepatitis B virus, 
and human immunodeficiency virus (HIV) and high preva-
lence of chronic viral infection (10).
The liver converts methadone into an inactive metabolite, 
which is why it is important to monitor the liver physiolog-
ical capacity during MMT. The liver’s physiological deficit 
could increase the amount of unmetabolized methadone 
and its toxic potential due to the chronic overdose (11). Al-
though liver biopsy has been the gold standard for the di-
agnosis and quantification of liver damage (fibrosis), it has 
several disadvantages (12-14). Transient elastography, on 
the other hand, predicts the severity of hepatic fibrosis but 
not the liver metabolic capacitance (15). Cheap and easy-
to-obtain alternatives to these approaches for evaluation 
of liver dysfunction are aspartate aminotransferase (AST) 
to platelet ratio (APRI) index (16) and fibrosis 4 (FIB-4) score 
(17), both non-invasive fibrosis indices using data from 
routine biochemical and hematological analyses. These 
tools have significant sensitivity and specificity and can be 
applied during each visit (16,17). FIB-4 score and APRI in-
dex have been used in a variety of models for liver damage 
prediction (13,18,19).
Methadone metabolism in opiate addicts undergoing 
MMT was studied by Wu et al, but only in patients with 
HCV infection (10). No study has used APRI and FIB-4 as 
predictors of liver damage in this group of patients and 
compared them with HCV infection status. Our aim was to 
investigate methadone metabolism properties by measur-
ing plasma and urine concentrations of methadone and 
its most common inactive metabolite, 2-ethylidene-1,5-di-
methyl-3,3-diphenylpyrrolidine (EDDP), and to examine if 
liver dysfunction influences methadone metabolism. The 
second aim of our study was to assess whether FIB-4 score 
and APRI index are useful in evaluating liver damage in pa-
tients with heroin addiction undergoing MMT treatment. 
Our hypothesis was that, due to disrupted liver metabolic 
capacity, patients with liver dysfunction taking the same 
initial dose of methadone as the patients with normal liver 
function would have greater concentration of active meth-
adone in biological samples.
PatieNtS aND MethoDS
Participants and materials
This cross-sectional study was conducted in the outpatient 
clinic of Croatian Public Health Institute of Split-Dalmatia 
County between 2013 and 2016. Adult male patients with 
heroin addiction undergoing MMT were assessed for eligi-
bility and 74 patients met the inclusion criteria (Figure 1). 
After 18 (25%) participants were excluded because of low 
compliance or lack of necessary data from medical records 
(Supplementary Table 1), the final sample consisted of 56 
participants, who were divided into groups according to 
their HCV status (positive, negative, or clinical remission 
[CR]; APRI index (<0.7 and ≥0.7); and FIB-4 score (<1.45, 
1.45-3.25, >3.25) (Figure 1).
The study was conducted in accordance with the Declara-
tion of Helsinki and approved by the Ethics Committee of 
the University Hospital Split, Croatia (No. 530-01/12-01/164, 
December 6, 2012). All participants received detailed infor-
mation and signed a written informed consent for partici-
pation and data publication.
Sample size was determined on the basis of a previous 
study (10) and a pilot study, which included 19 adult male 
opiate addicts aged ≥21 years and treated within the out-
patient MMT program of the Institute for Public Health of 
Split-Dalmatia County. Inclusion and exclusion criteria and 
samples collection were the same as in the present study.
Methods
Demographic, clinical, and laboratory assessments 
were made at the initial meeting with the partici-
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pants. The data on age, MMT dose (in milligrams), and treat-
ment duration (in months) were obtained from medical 
records. Height and weight were measured as part of clini-
cal examination, and body mass index (BMI) and weight-
based dose were calculated. Interviewer-administered as-
sessment was conducted for each participant. Aspartate 
aminotransferase (AST, reference range <41 IU/L), alanine 
transaminase (ALT, reference range <41 IU/L), and platelet 
count (reference range 150-400 × 109/L) were determined 
from the blood samples analyzed at the University of Split, 
Department of Pathology and Forensic Medicine.
HCV status is a widely accepted predictor of liver damage 
(10,20). APRI index (16) and FIB-4 score (17) were used in 
our study as non-invasive measures for prediction of liver 
damage. APRI index ≥0.7 had sensitivity of 77% and speci-
ficity of 72% for predicting significant hepatic fibrosis (16). 
FIB-4 score <1.45 had 90% negative predictive value for 
the advanced fibrosis, while FIB-4 ≥ 3.25 had 97% speci-
ficity and 65% positive predictive value for advanced fi-
brosis (17).
Methadone and EDDP concentrations were determined in 
biological samples obtained from the participants at their 
regular check-ups. The recommended therapeutic dose for 
each individual was previously determined on the basis of 
their clinical presentation and was not modified for at least 
last six months. Urine samples were obtained before oral 
methadone administration, and blood and urine samples 
were obtained 90 minutes after methadone administra-
tion. The samples were stored at 4°C and analyzed within 
1-4 days.
Gas chromatography/mass spectrometry drug analysis 
was performed using a Shimadzu GC-2010 instrument 
(Kyoto, Japan) as previously described (21). Briefly, race-
mic methadone hydrochloride and EDDP perchlorate 
were obtained from Lipomed AG (Arlesheim, Switzer-
land). Sera samples were prepared for analysis using a 
liquid-liquid extraction method, and 2 mL was added to 
pre-labeled Toxi Tubes A (Varian, Palo Alto, CA, USA) (22). 
The samples were extracted on the rotor and centrifuged. 
The supernatants were separated in glass test tubes and 
evaporated under a stream of inert gas of nitrogen to dry-
Figure 1. Study flowchart. hiV – human immunodeficiency virus; hBV – hepatitis B virus; Cr – clinical remission; aPri – aspartate 
transaminase to platelet index, FiB-4 – Fibrosis-4 score. *For reasons of exclusion please see Supplementary table 1.
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ness. The dry residue was dissolved in 30 μL chloroform 
and transferred to a glass vial. Standard methadone and 
EDDP solutions were used for method validation. After 
EDDP and methadone plasma and urine concentration 
levels were measured, metabolic ratio (MR) was calculat-
ed as the concentration ratio of EDDP to methadone in 
urine specimens. The MR is unitless and represents the 
relationship of methadone to its metabolite at the time 
of collection (23).
Statistical analysis
MR in urine, and MTD and EDDP concentration in plasma, 
were log10-transformed because the data followed log-
normal distribution. If data are log transformed, the dif-
ference between means of data logarithms becomes a 
ratio, which when transformed back to the original scale 
becomes the ratio of two geometric means (24,25). There-
fore, the effect sizes in this study are expressed as geo-
metric mean ratios and 95% confidence intervals (CI). Sig-
nificance of difference between continuous variables was 
analyzed using t test, linear test for trend, and multiple 
linear regression. Descriptive statistics are expressed as a 
median and interquartile range for continuous variables 
or as a percentage for proportions. Explanatory power (R2) 
represents the determination coefficient of linear models, 
t test model, or multiple linear regression. Model selec-
tion was performed using the Akaike information criteri-
on (AIC) (26). The level of significance was set at P < 0.05. 
Study sample size was determined so that study had 80% 
power to detect small effect size of Cohen’s f2 = 0.15. Sta-
tistical analysis was performed using GraphPad Prism 7.02 
software for Windows (GraphPad Software, La Jolla, CA, 
USA), and power calculation was performed using the 
G*Power software (Heinrich Heine University, Dusseldorf, 
Germany). Bayesian factors (BF) were calculated by using 
JASP software (JASP Team 2017, version 0.8.3.1, https://
jasp-stats.org).
reSultS
Twenty-four of 56 participants (43%) were HCV positive 
(Table 1). All participants were treated with a median 
methadone dose of 80 mg (range: 50-100 mg). Median 
duration of MMT was 90 months (range: 46-173 months), 
without any significant difference in dose or treatment 
duration between HCV-positive and HCV-negative group. 
APRI index higher than 0.7 was found in 27 (37.5%) partici-
pants and FIB-4 higher than 3.25 in 8 (14.28%) participants 
(Table 1). Median age of the entire cohort was 43 years 
(range: 39-50 years), and there were no significant differ-
ences between the groups in BMI or the dose relative to 
patients’ body weight.
Chronic hCV infection and methadone metabolism
MR in urine after methadone administration decreased 
linearly with HCV infection status by the average factor 
of 1.67 (95% CI 1.24 to 2.24, P = 0.001; Figure 2A). A simi-
lar trend was observed before methadone administra-
tion, but the difference was not significant (fold-change in 
geometric mean ratio = 1.17, 95% CI 0.058-1.08, P = 0.153, 
BF = 0.7; Figure 2B). There were no differences in metha-
done plasma concentration in patients with different HCV 
infection status (Figure 2C). Plasma EDDP after metha-
done ingestion decreased with the HCV infection status 
by the average factor of 2.2 (95% CI 1.03-4.74, P = 0.043) 
(Figure 2D).
taBle 1. Demographic and laboratory findings (median and interquartile range) in study participants on methadone maintenance 
treatment divided according to hepatitis C virus (hCV) infection, aspartate transaminase to platelet ratio index (aPri), and fibrosis-4 
score
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aPri index and methadone metabolism
MR in urine after methadone administration decreased in 
participants with APRI index ≥0.7 by the average factor of 
2.12 (95% CI 1.2- 3.74, P = 0.010) compared with patients 
with APRI index <0.7 (Figure 3A). Although a similar trend 
was observed before methadone administration (1.52, 95% 
CI 0.85-2.68, P = 0.154, BF = 0.65), the difference was not sig-
nificant (Figure 3B). Methadone plasma concentration non-
significantly increased in participants with APRI index ≥0.7 
(geometric mean ratio 0.572, 95% CI 0.179 to 1.819, P = 0.338, 
BF = 0.4) (Figure 3C). Plasma EDDP concentration in patients 
with APRI index ≥0.7 significantly decreased by the average 
factor of 6.16 (95% C1.57-24, P = 0.009) (Figure 3D).
FiB-4 score and methadone metabolism
MR before and after oral methadone intake decreased 
with the severity of FIB-4 score by the average factor of 
1.57 (95% CI 1.08 to 2.27, P = 0.018) and 1.63 (95% CI 1.15 to 
2.44, P = 0.008), respectively (Figure 4A and 4B). Methadone 
plasma concentration was not associated with the severity 
of FIB-4 score (Figure 4C), whereas plasma EDDP concen-
tration decreased with increasing FIB-4 score by the factor 
of 3.53 (95% CI 1.43 to 8.72, P = 0.007) (Figure 4D).
Figure 2. Methadone (MtD) pharmacokinetics stratified by hepatitis C virus (hCV) infection status. (A) a significant decrease in 
Mr in urine samples after methadone administration (β = -0.2215, 95% Ci 1.24 to 2.24, P = 0.001). (B) a non-significant difference in 
logarithmically transformed metabolic ratio (Mr) in urine samples before methadone administration (β = -0.0994, 95% confidence 
interval [Ci] 0.058 to 1.08, P = 0.153, BF = 0.7). (C) a non-significant difference in logarithmically transformed methadone plasma 
concentration (β = 0.0275, 95% Ci -0.2481 to 0.3032, P = 0.841, BF = 0.27). (D) a significant difference in logarithmically transformed 
plasma concentration of 1,5-dimethyl-3,3-diphenylpyrrolidine (eDDP) (β = -0.3436, 95% Ci 1.03 to 4.74, P = 0.043). β – slope param-
eter of log linear model, BF – Bayesian factor.
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Comparison of liver damage indices
To determine which of the liver damage indices better ex-
plains changes in methadone metabolism (Table 2), we 
compared them in terms of explanatory power (R2) for dif-
ferences in methadone and EDDP plasma concentration 
and MR in urine. Overall, the best explanatory power was 
shown by FIB-4 score. R2 for stratification of methadone 
plasma concentration of FIB-4 was two times higher than 
that for APRI and 6 times higher than that for HCV infection 
status. For EDDP plasma concentration, non-invasive fibro-
sis indices offered better explanatory power than the HCV 
infection status (Table 2). For MR determination in urine, 
the best stratification variable was HCV infection status, al-
though the explanatory power of all liver damage indices 
remained rather low. All three predictors better explained 
taBle 2. explanatory power (r2) of stratification variables of liver damage predictors including hepatitis C virus (hCV) infection 
status, aspartate transaminase to platelet ratio index (aPri), and fibrosis-4 score for difference in plasma methadone, plasma 2- 
ethylidene-1,5-dimethyl-3,3-diphenylpyrroldine (eDDP), and urine metabolic ratio
Stratification variables
Main outcome measures hCV status aPri fibrosis-4 score
Plasma methadone (mg/L, %) 0.7  2.1  4.2
Plasma EDDP (mg/L, %) 7.3 11.7 12.6
Urine metabolic ratio (%) 17.7 11.6 13.9
Figure 3. Methadone (MtD) pharmacokinetics stratified by aspartate transaminase to platelet ratio (aPri) index. a significant 
decrease in logarithmically transformed metabolic ratio (Mr) in urine samples in patients with aPri index ≥7 compared with those 
with aPri index <0.7 after methadone administration (95% confidence interval [Ci] 0.12 to 3.74, P = 0.010). (A). a non-significant 
difference in Mr before methadone administration (95% Ci 0.85 to 2.68, P = 0.154, BF = 0.65) (B) a non-significant difference in 
logarithmically transformed methadone plasma concentration according to aPri status (95% Ci 0.179 to 1.819, P = 0.338, BF = 0.4). (C) 
a significant difference in logarithmically transformed plasma 1,5-dimethyl-3,3-diphenylpyrrolidine metabolite (eDDP) (95% Ci 57 to 
24, P = 0.009). (D) BF – Bayesian factor.
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differences in urine MR and plasma EDDP than plasma 
methadone. The optimal model for predicting methadone 
metabolism based on HCV, FIB4, and other demographic 
and morphometric characteristics of our participants (Sup-
plementary Table 2) predicted log of MR after methadone 
intake based on HCV status, FIB-4, and participant age, with 
an explanatory power of 27% (Supplementary Table 3).
DiSCuSSioN
We found a significant association between non-invasive 
predictors of liver damage and a decrease in urine and 
plasma EDDP concentration, probably due to impaired liv-
er methadone metabolism. MR changes could be attribut-
ed to lower overall EDDP concentration rather than higher 
methadone concentration, which indicates diminished liv-
er capacity for methadone processing.
There was no difference in plasma methadone levels be-
tween participants with different HCV infection status, FIB-4 
score, or APRI index. This could be explained by metha-
done’s lipophilic properties and high volume of distribution 
(27). Methadone concentration in tissues is higher than in 
plasma, with only about 2% of absorbed methadone re-
maining in the plasma compartment (27). Therefore, it is 
understandable that we could not find a difference in the 
plasma methadone concentration between the groups; 
plasma methadone represents a small fraction of the total 
methadone concentration following oral administration.
Our results do not confirm previous findings (20) of high-
er initial methadone doses in HCV-positive patients. In our 
study, the initial methadone dose was around 1 mg/kg re-
gardless of BMI, treatment duration, HCV infection status, 
or participant’s age and did not differ between the groups. 
Figure 4. Methadone (MtD) pharmacokinetics stratified according to fibrosis-4 (FiB-4) score. a significant decrease in logarithmi-
cally transformed metabolic ratio (Mr) with rising FiB-4 score before (β = -0.3567, 95% confidence interval [Ci] 1.08 to 2.27, P = 0.018) 
(A) and after methadone administration (β = -0.2236, 95% Ci 1.15 to 2.44, P = 0.008) (B). a non-significant difference in logarithmically 
transformed plasma methadone concentration according to FiB-4 score (β = -0.0543, P = 0.749, BF = 0.28) (C). a significant decrease 
in plasma 1,5-dimethyl-3,3-diphenylpyrrolidine (eDDP) in patients with high FiB-4 score (β = -0.5478, 95% Ci = 1.43 to 8.72, P = 0.007) 
(D). β – slope parameter of log linear model, BF – Bayesian factor.
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However, it seems that this dose if orally administered does 
not provide the same drug amount or concentration to all 
patients. This could be explained by different pharmacoki-
netic profiles in patients with APRI≥0.7 index and FIB-4 
score >3.25, hence depending on an individual hepatic ca-
pacity for methadone metabolism.
Although MR in urine, as an overall measure of methadone 
metabolic capacity, and EDDP plasma concentration de-
creased linearly with HCV infection status, we did not ob-
serve any differences in methadone plasma concentration. 
These findings differ from the findings by Wu et al (10), 
who reported higher plasma methadone concentration 
in patients with HCV infection, together with lower MR. 
These discrepancies may be attributed to differences in 
race, sample size, or inclusion criteria. Unlike Wu et al (10), 
we divided the participants according to HCV status, dis-
tinguishing HCV-positive from those in remission and ex-
cluded patients co-infected with hepatitis B virus or HIV. Fi-
nally, the difference could be attributed to the surprisingly 
high rate of around 95% HCV-positive patients in the study 
by Wu et al (10), compared with 43% in our study.
Furthermore, in our study, patients with APRI index ≥0.7 
and FIB-4 score 1.45-3.25 and >3.25 had decreased MR in 
urine and EDDP plasma concentration. Although there are 
several reports on the usefulness of FIB-4 score and APRI 
index in a variety of models for liver damage prediction 
(13,19), this is, to the best of our knowledge, the first re-
port evaluating the use of FIB-4 score and APRI index in 
methadone metabolism prediction and dose modification 
in heroin abusers undergoing MMT treatment.
The best explanatory power was obtained by FIB-4 score. 
APRI index had three times higher explanatory power for 
plasma methadone when compared with HCV infection 
status. These results suggest that indices of liver fibrosis 
better assess methadone metabolism in patients undergo-
ing MMT than clinical diagnosis of HCV infection status.
One of the study limitations is the small sample size, but the 
poor compliance and motivation of these patients should be 
taken into consideration when conducting this type of stud-
ies. Another limitation is the lack of female participants, who 
were not recruited due to small number of women treated 
at our institution. Blood samples before methadone admin-
istration were not collected because IV drug users often 
suffer from damaged blood vessels, which makes the sam-
pling difficult and sometimes impossible. Furthermore, the 
blood methadone concentration reaches the peak value of 
2.5 about 4 h after therapeutic dose administration, during 
which time participants become less compliant (28). These 
blood samples could have provided more information on liv-
er metabolic capacity and methadone body elimination. Ad-
ditionally, this study did not consider genetic influence of CY-
P3A4 and CYP2B6 and molecular properties of methadone 
elimination, which is an issue that merits further study.
In conclusion, this is the first study evaluating the use of 
APRI index and FIB-4 score in methadone metabolism pre-
diction and comparing these indices with HCV infection 
status. Liver fibrosis indices and HCV status were to a lesser 
extent associated with decreased methadone liver-medi-
ated metabolism in patients with heroin addiction suitable 
for MMT program. Therefore, calculation of these indices 
could be a potential tool for clinicians in everyday practice. 
Future research should assess the correlation between the 
mentioned variables and methadone-dosing regimen to 
determine whether these variables may be used to titrate 
methadone target doses in patients starting methadone 
maintenance program.
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